A Phase 3 interventional study of Doravirine, Tenofovir, Lamivudine and Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The multicenter, open label, randomized study will evaluate the safety and efficacy of a switch to MK-1439A (MK-1439 [doravirine] plus lamivudine and tenofovir disoproxil fumarate) in HIV-1-infected participants virologically suppressed on a protocol-specified antiretroviral regimen. The primary hypothesis is that a switch to doravirine, tenofovir, lamivudine will be non-inferior to continuation of the regimen at Screening for 24 weeks, as assessed by the proportion of participants maintaining HIV-1 ribonucleic acid (RNA) \<50 copies/mL. The Base Study results will be based on the first 48 weeks of this ongoing study.
Three optional study extensions are planned. Study Extension 1 will evaluate safety of the switch to doravirine, tenofovir, lamivudine for an additional 2 years beyond the Base Study. Study Extensions 2 and 3 will evaluate safety of the switch to doravirine, tenofovir, lamivudine until doravirine, tenofovir, lamivudine becomes locally available, or 4 years beyond Study Extension 1, whichever comes first.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria include, but are not limited to:
Exclusion Criteria:
Exclusion Criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for \>=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
Drug: Doravirine, Tenofovir, Lamivudine · Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor · Drug: Baseline regimen of cobicistat-boosted elvitegravir · Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor · Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for \>=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
Drug: Doravirine, Tenofovir, Lamivudine · Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor · Drug: Baseline regimen of cobicistat-boosted elvitegravir · Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor · Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Drug pages: Doravirine · Tenofovir · Lamivudine
Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Also known as: Doravirine (PIFELTRO™), Doravirine/Lamivudine/Tenofovir disoproxil fumarate (DELSTRIGO™), MK-1439A
Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Percentage of Participants Maintaining Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Immediate Switch to MK-1439A arm: Week 48; Delayed Switch to MK-1439A arm: Week 24
Mean Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C)
To evaluate the effect on fasting LDL-C of an immediate switch to DOR/3TC/TDF on Study Day 1 compared with continuation of a ritonavir-boosted, PI-based regimen, as measured by mean change from baseline in each treatment group. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline and Week 24
Mean Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid lowering therapy.
Time frame: Baseline and Week 24
Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Week 24
Mean Change From Baseline in Cluster of Differentiation (CD4) Cell Counts
The mean change from baseline in CD4 cell counts was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued due to lack of efficacy. Cell counts were measured and expressed as cells/mm\^3, and percent change was then calculated. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Immediate Switch to MK-1439A arm: Baseline and Week 48; Delayed Switch to MK-1439A arm: Baseline and Week 24
Mean Change From Baseline in Cluster of Differentiation (CD4) Cell Counts
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued due to lack of efficacy. Cell counts were measured and expressed as cells/mm\^3, and percent change was then calculated. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Baseline and Week 24
Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Immediate Switch to MK-1439A arm: Week 48; Delayed Switch to MK-1439A arm: Week 24
Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL
To evaluate the immunological effect of an immediate switch to MK -1439A on Study Day 1 compared with continuation of a ritonavir boosted, PI-based regimen, as measured by the proportion of subjects maintaining HIV-1 RNA below the limit of quantification (BLoQ) by the Abbott RealTime HIV-1 Assay (\<40 copies/mL) in both treatment groups.
Time frame: Immediate Switch to MK-1439A arm: Week 24; Delayed Switch to MK-1439A arm: Week 24
Percentage of Participants With HIV-1 RNA >=50 Copies/mL
The percentage of participants in each arm achieving HIV-1 RNA levels \>=50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach.
Time frame: Immediate Switch to MK-1439A arm: Week 48; Delayed Switch to MK-1439A arm: Week 24
Percentage of Participants Experiencing ≥1 Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to week 24
Percentage of Participants Experiencing ≥1 Serious Adverse Event (SAE)
A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
Time frame: Up to 24 weeks
Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 24
| Milestone | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Started | 450 | 223 |
| Treated | 447 | 223 |
| Completed | 427 | 209 |
| Not completed | 23 | 14 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Protocol violation | 1 | 4 |
| Withdrew: Withdrawal by subject | 6 | 1 |
| Withdrew: Randomized, not treated | 3 | 0 |
| Milestone | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Started | 427 | 209 |
| Completed | 407 | 202 |
| Not completed | 20 | 7 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Lack of efficacy | 5 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Milestone | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Started | 398 | 202 |
| Completed | 357 | 179 |
| Not completed | 41 | 23 |
| Withdrew: Adverse event | 7 | 5 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 5 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Non-compliance with study drug | 3 | 0 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 21 | 7 |
| Milestone | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Started | 303 | 154 |
| Completed | 129 | 78 |
| Not completed | 174 | 76 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Availability of study medication locally | 152 | 64 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 10 | 3 |
| Milestone | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Started | 84 | 43 |
| Completed | 69 | 39 |
| Not completed | 15 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Availability of study medication locally | 11 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Maintaining Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL | 90.8 | 94.6 |
To evaluate the effect on fasting LDL-C of an immediate switch to DOR/3TC/TDF on Study Day 1 compared with continuation of a ritonavir-boosted, PI-based regimen, as measured by mean change from baseline in each treatment group. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| mg/dL | Immediate Switch (Ritonavir--boosted, PI-based) Group (ISG) | Delayed Switch (Ritonavir-boosted, PI-based) Group (DSG) |
|---|---|---|
| Baseline | 108.82 ± 34.21 | 109.00 ± 33.58 |
| Change from Baseline | -16.54 ± 23.10 | -1.94 ± 25.74 |
Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid lowering therapy.
| mg/dL | Immediate Switch (Ritonavir--boosted, PI-based) Group (ISG) | Delayed Switch (Ritonavir-boosted, PI-based) Group (DSG) |
|---|---|---|
| Baseline | 139.14 ± 42.12 | 137.99 ± 38.46 |
| Change from Baseline | -24.74 ± 29.26 | -1.31 ± 28.45 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL | 93.7 | 94.6 |
The mean change from baseline in CD4 cell counts was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued due to lack of efficacy. Cell counts were measured and expressed as cells/mm\^3, and percent change was then calculated. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
| cells/mm^3 | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Baseline | 660.5 ± 293.4 | 655.6 ± 279.3 |
| Change from Baseline | 13.9 ± 168.1 | 18.0 ± 157.7 |
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued due to lack of efficacy. Cell counts were measured and expressed as cells/mm\^3, and percent change was then calculated. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
| cells/mm^3 | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Baseline | 664.5 ± 300.7 | 655.6 ± 279.3 |
| Change from Baseline | 5.1 ± 174.9 | 18.0 ± 157.7 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL | 89.7 | 93.3 |
To evaluate the immunological effect of an immediate switch to MK -1439A on Study Day 1 compared with continuation of a ritonavir boosted, PI-based regimen, as measured by the proportion of subjects maintaining HIV-1 RNA below the limit of quantification (BLoQ) by the Abbott RealTime HIV-1 Assay (\<40 copies/mL) in both treatment groups.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL | 92.8 | 93.3 |
The percentage of participants in each arm achieving HIV-1 RNA levels \>=50 copies/mL was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA >=50 Copies/mL | 1.6 | 1.8 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Experiencing ≥1 Adverse Event (AE) | 68.9 | 52.5 |
A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Experiencing ≥1 Serious Adverse Event (SAE) | 2.9 | 3.6 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of Participants | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) |
|---|---|---|
| Percentage of Participants Discontinuing From Study Medication Due to an AE(s) | 2.5 | 0.4 |
Collected over Up to ~338 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ISG Base Study Weeks 0-24 | 1/450 (0.2%) | 13/447 (2.9%) | 100/447 (22.4%) |
| DSG Base Study Weeks 0-24 | 0/223 (0%) | 8/223 (3.6%) | 28/223 (12.6%) |
| ISG Base Study Weeks 24-48 | 0/427 (0%) | 11/427 (2.6%) | 63/427 (14.8%) |
| DSG Base Study Weeks 24-48 | 0/209 (0%) | 4/209 (1.9%) | 33/209 (15.8%) |
| ISG Study Extension 1 | 1/398 (0.3%) | 37/398 (9.3%) | 107/398 (26.9%) |
| DSG Study Extension 1 | 0/202 (0%) | 13/202 (6.4%) | 57/202 (28.2%) |
| ISG Study Extension 2 | 3/303 (1%) | 13/303 (4.3%) | 24/303 (7.9%) |
| DSG Study Extension 2 | 0/154 (0%) | 7/154 (4.5%) | 11/154 (7.1%) |
| ISG Study Extension 3 | 0/84 (0%) | 3/84 (3.6%) | 9/84 (10.7%) |
| DSG Study Extension 3 | 0/43 (0%) | 1/43 (2.3%) | 3/43 (7%) |
| Event | ISG Base Study Weeks 0-24 | DSG Base Study Weeks 0-24 | ISG Base Study Weeks 24-48 | DSG Base Study Weeks 24-48 | ISG Study Extension 1 | DSG Study Extension 1 | ISG Study Extension 2 | DSG Study Extension 2 | ISG Study Extension 3 | DSG Study Extension 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 0/303 | 0/154 | 0/84 | 1/43 |
| PneumoniaInfections and infestations | 1/447 | 3/223 | 0/427 | 0/209 | 1/398 | 2/202 | 1/303 | 0/154 | 0/84 | 0/43 |
| COVID-19Infections and infestations | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 0/303 | 1/154 | 1/84 | 0/43 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/447 | 0/223 | 0/427 | 0/209 | 1/398 | 0/202 | 0/303 | 0/154 | 1/84 | 0/43 |
| NephrolithiasisRenal and urinary disorders | 0/447 | 0/223 | 0/427 | 0/209 | 1/398 | 0/202 | 0/303 | 0/154 | 1/84 | 0/43 |
| AppendicitisInfections and infestations | 0/447 | 0/223 | 1/427 | 1/209 | 1/398 | 2/202 | 1/303 | 0/154 | 0/84 | 0/43 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/447 | 0/223 | 0/427 | 0/209 | 3/398 | 0/202 | 0/303 | 0/154 | 0/84 | 0/43 |
| Coronary artery stenosisCardiac disorders | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 0/303 | 1/154 | 0/84 | 0/43 |
| Myocardial infarctionCardiac disorders | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 0/303 | 1/154 | 0/84 | 0/43 |
| Retinal detachmentEye disorders | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 0/303 | 1/154 | 0/84 | 0/43 |
| Event | ISG Base Study Weeks 0-24 | DSG Base Study Weeks 0-24 | ISG Base Study Weeks 24-48 | DSG Base Study Weeks 24-48 | ISG Study Extension 1 | DSG Study Extension 1 | ISG Study Extension 2 | DSG Study Extension 2 | ISG Study Extension 3 | DSG Study Extension 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 33/447 | 12/223 | 19/427 | 9/209 | 51/398 | 29/202 | 5/303 | 2/154 | 0/84 | 0/43 |
| COVID-19Infections and infestations | 0/447 | 0/223 | 0/427 | 0/209 | 0/398 | 0/202 | 4/303 | 6/154 | 7/84 | 3/43 |
| HeadacheNervous system disorders | 29/447 | 5/223 | 11/427 | 14/209 | 22/398 | 13/202 | 2/303 | 3/154 | 0/84 | 0/43 |
| DiarrhoeaGastrointestinal disorders | 20/447 | 5/223 | 13/427 | 9/209 | 18/398 | 11/202 | 3/303 | 0/154 | 1/84 | 0/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/447 | 5/223 | 8/427 | 3/209 | 21/398 | 4/202 | 5/303 | 1/154 | 1/84 | 0/43 |
| Back painMusculoskeletal and connective tissue disorders | 9/447 | 4/223 | 16/427 | 1/209 | 21/398 | 9/202 | 7/303 | 2/154 | 0/84 | 0/43 |
| Age, Continuous(Years) | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) | Total |
|---|---|---|---|
| Mean | 43.1 ± 10.1 | 43.7 ± 10.6 | 43.3 ± 10.3 |
| Sex: Female, Male(Participants) | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) | Total |
|---|---|---|---|
| Female | 75 | 29 | 104 |
| Male | 375 | 194 | 569 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) | Total |
|---|---|---|---|
| Hispanic or Latino | 98 | 43 | 141 |
| Not Hispanic or Latino | 347 | 177 | 524 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race (NIH/OMB)(Participants) | Immediate Switch Group (ISG) | Delayed Switch Group (DSG) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 2 | 7 |
| Asian | 17 | 8 | 25 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 56 | 34 | 90 |
| White | 346 | 168 | 514 |
| More than one race | 25 | 11 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2015 to primary completion in Feb 2018, 32 months.
Results were first posted in Apr 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Tenofovir · Lamivudine